MINDCURE Shares Update on Strong Financial Position, Near Term Revenue Drivers and Timeline for iSTRYM’s Market Launch, Delivering Mental Wealth

MINDCURE is well-positioned to capitalize on its near-term revenue strategy, complete beta testing and launch of…

MINDCURE Announces Partnership with SOMA Breath Inc. to License its Breathwork Program and Develop Custom Breathwork for Psychedelic-Assisted Psychotherapies within iSTRYM

Breathwork has shown promise at both replicating the experience of psychedelics and helping patients to integrate…

MINDCURE Announces Experienced Finance Executive Michael Wolfe as CFO and appoints Larissa Chaikowsky to its Board of Directors

Mr. Wolfe has extensive capital markets and debt and equity financing experience; Ms. Chaikowsky, the COO…

MINDCURE Partners its iSTRYM Technology with LUCID to Discover and Create Proprietary Music Experiences for Use During Psychedelic-Assisted Therapy Sessions

LUCID’s technology platform unites music, AI and research in neuroscience to create personalized digital music therapy…

MINDCURE Announces Partnership with Speak Ai to Enhance iSTRYM, the Company’s Psychedelic Digital Therapeutics Technology Platform

Utilizing Speak Ai’s technology, iSTRYM will provide Ai-driven intelligence to help therapists identify the most efficient…

MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors

ATMA Was The First Private Sector Service Provider In Canada Conducting Legal Psychedelic-Assisted Therapy For A Palliative Care…

MINDCURE Files Provisional Patent Application For iSTRYM, its Proprietary AI Digital Therapeutics (DTx) SaaS Platform, Designed To Enhance Effectiveness Of Psychedelic-Assisted Therapies For Practitioners And Patients

Company Now Is In Two High Growth Rate Global Markets With iSTRYM In The DTx Market,…

Ty Tashiro joins MINDCURE as the Senior Translational and Psychometric Architect for iSTRYM’s AI-Driven Psychedelic Digital Therapeutic Technology

The award-winning professor and psychology Ph.D. is an expert in translating psychological research and science into…

MINDCURE Names Tarik Lebbadi as Chief Operating Officer

An accomplished international operator, Mr. Lebbadi led the medical division for Johnson & Johnson and has…

MINDCURE Receives Unconditional Ethics Approval for its Psychedelic Integration Protocol Research Study

VANCOUVER, BC, March 9, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”)…

MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury

This potential treatment opportunity was confirmed by the company’s bioinformatics platform, PsyCollage VANCOUVER, BC, March 4, 2021 /CNW/…

MINDCURE Announces Manufacturing of Synthetic Ibogaine to be Used in Company’s Clinical Research

The Company expects to have ibogaine manufactured and in use for research by Q4. VANCOUVER, BC, March…